Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Anthelmintic Drugs Market Poised To Hit $4.31 Billion By 2030 With A 5.2% CAGR
The anthelmintic drugs market has demonstrated robust growth over recent years. It is projected to increase from $3.34 billion in 2025 to $3.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This market’s historical expansion is largely attributable to the widespread occurrence of parasitic infections, constrained availability of advanced anthelmintic drugs, continued reliance on traditional drug classes, a rising understanding of helminth infections, and the development of hospital and clinic infrastructure.
The anthelmintic drugs market size is anticipated to experience robust expansion over the forthcoming years. It is projected to reach $4.32 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This projected growth stems from several factors, including the development of novel anthelmintic compounds, a greater embrace of combination therapies, increasing applications in veterinary and livestock sectors, the widening reach of online and retail pharmacy channels, and government-led initiatives for parasite control programs. Significant trends expected during this period include a rising prevalence of helminth infections across human and animal populations, the growing preference for oral anthelmintics and injectable formulations, an escalating demand for veterinary anthelmintics in managing livestock, the continued expansion of retail and online pharmacy outlets for these medications, and a strategic focus on combination therapies and broad-spectrum anthelmintics.
Get A Free Sample Report With In-Depth Market Insights:
Anthelmintic Drugs Market Growth Drivers: What’s Behind The Acceleration?
A significant occurrence of parasitic infections is anticipated to boost the expansion of the anthelmintic drugs market in the future. These infections are illnesses resulting from organisms like protozoa, worms, or ectoparasites residing on or within a host. Factors contributing to parasitic infections include insufficient sanitation, tainted food or water, direct exposure to infected people or animals, poor hygiene, and limited availability of clean resources. Medications known as anthelmintic drugs are administered to address infections caused by parasitic worms, efficiently targeting and removing these parasites from the host. These drugs operate by disturbing the parasites’ bodily functions, which results in their expulsion or demise. For example, in September 2025, information released by the Centers for Disease Control and Prevention, a US-based national public health agency, indicated that by September 16, 2025, the CDC had recorded 990 cases of cyclosporiasis contracted within the United States. Consequently, the widespread occurrence of parasitic infections is propelling the expansion of the anthelmintic drugs market.
Anthelmintic Drugs Market Segment Trends And Revenue Contributors
The anthelmintic drugs market covered in this report is segmented –
1) By Drug Class: Benzimidazoles, Macrocyclic lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Infection Type: Nematode Infections, Cestode Infections, Trematode Infections, Mixed Infections
4) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Online Pharmacies, Veterinary Clinics And Supply Stores
5) By Application: Human Anthelmintics, Veterinary Anthelmintics
Subsegments:
1) By Benzimidazoles: Albendazole, Mebendazole, Fenbendazole, Oxfendazole, Thiabendazole
2) By Macrocyclic Lactones: Ivermectin, Moxidectin, Doramectin, Eprinomectin, Milbemycin Oxime
3) By Pyrazinoisoquinolones: Praziquantel, Cysticide
4) By Tetrahydropyrimidines: Pyrantel Pamoate, Pyrantel Tartrate
5) By Other Drug Classes: Imidazothiazoles, Aminoacetonitrile Derivatives, Spiroindoles, Arsenicals
Anthelmintic Drugs Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the anthelmintic drugs market are focusing on creating advanced solutions, such as targeted, evidence-based deworming programs, to enhance parasite control, mitigate drug resistance, and encourage the sustainable application of anthelmintics, departing from conventional blanket deworming strategies that often involve frequent, untargeted treatments. These focused deworming programs employ diagnostic testing, parasite load evaluations, and strategic dosing schedules to maximize treatment effectiveness while minimizing environmental and resistance risks. For example, in April 2025, Zoetis Inc., a US-based animal health company, launched the “Buy Less Dewormer” campaign aimed at equine populations, advocating for evidence-based parasite management. This program integrates educational resources with guidelines on fecal egg count monitoring and strategic anthelmintic selection; it operates by advising horse owners and veterinarians to administer treatments solely when essential, determined by the parasite burden and risk assessment. Its distinct features encompass integrated educational materials, recommendations for risk-based treatments, and support for responsible anthelmintic stewardship. The applications extend to equine herd health management, the prevention of parasite resistance, and optimized deworming timetables, yielding benefits such as reduced anthelmintic overuse, improved parasite control results, decreased costs for owners, and the promotion of lasting drug efficacy.
Anthelmintic Drugs Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company
View The Full Anthelmintic Drugs Market Report:
Anthelmintic Drugs Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the anthelmintic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthelmintic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
